Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma

Author:

Haydu Lauren E.1,Lo Serigne N.23,McQuade Jennifer L.4,Amaria Rodabe N.4,Wargo Jennifer1,Ross Merrick I.1,Cormier Janice N.1,Lucci Anthony1,Lee Jeffrey E.1,Ferguson Sherise D.5,Saw Robyn P.M.236,Spillane Andrew J.237,Shannon Kerwin F.27,Stretch Jonathan R.237,Hwu Patrick8,Patel Sapna P.4,Diab Adi4,Wong Michael K.K.4,Glitza Oliva Isabella C.4,Tawbi Hussein4,Carlino Matteo S.239,Menzies Alexander M.237,Long Georgina V.237,Lazar Alexander J.10111213,Tetzlaff Michael T.1013,Scolyer Richard A.236,Gershenwald Jeffrey E.1,Thompson John F.237,Davies Michael A.4

Affiliation:

1. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

2. Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia

3. Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia

4. Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

5. Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX

6. Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

7. Royal North Shore Hospital, Sydney, New South Wales, Australia

8. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

9. Department of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia

10. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

11. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

12. Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX

13. Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

PURPOSE Improved understanding of the incidence, risk factors, and timing of CNS metastasis is needed to inform surveillance strategies for patients with melanoma. PATIENTS AND METHODS Clinical data were extracted from the databases of 2 major melanoma centers in the United States and Australia for 1,918 patients with American Joint Committee on Cancer (AJCC) 8th edition stage III melanoma, diagnosed from 1998-2014, who had (negative) baseline CNS imaging within 4 months of diagnosis. The cumulative incidence of CNS metastasis was calculated in the presence of the competing risk of death, from stage III presentation and at benchmark time points 1, 2, and 5 years postdiagnosis. RESULTS At a median follow-up of 70.2 months, distant recurrence occurred in 711 patients (37.1%). The first site of distant metastasis was CNS only for 3.9% of patients, CNS and extracranial (EC) for 1.8%, and EC only for 31.4%. Overall, 16.7% of patients were diagnosed with CNS metastasis during follow-up. The cumulative incidence of CNS metastasis was 3.6% (95% CI, 2.9% to 4.6%) at 1 year, 9.6% (95% CI, 8.3% to 11.0%) at 2 years, and 15.8% (95% CI, 14.1% to 17.6%) at 5 years. The risk of CNS metastasis was significantly influenced by patient sex, age, AJCC stage, primary tumor site, and primary tumor mitotic rate in multivariable and conditional analyses. High primary tumor mitotic rate was significantly associated with increased risk of CNS metastasis at diagnosis and all subsequent time points examined. CONCLUSION Similar rates of CNS metastasis were observed in 2 large, geographically distinct cohorts of patients with stage III melanoma. The results highlight the importance of primary tumor mitotic rate. Furthermore, they provide a framework for developing evidence-based surveillance strategies and evaluating the impact of contemporary adjuvant therapies on the risk of CNS metastasis development.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3